Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of N-Acetylglucosamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HK1 | P19367 | 3/20 | 0.48 |
| ▸ | HK2 | P52789 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Acetylglucosamine SCHEMBL27041116 | 1.00 | MAPK1 (0.58) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL19900502 | 1.00 | MAPK1 (0.58) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL28064772 | 1.00 | MAPK1 (0.58) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL27491227 | 1.00 | MAPK1 (0.58) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL5466652 | 1.00 | MAPK1 (0.58) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL21073206 | 1.00 | MAPK1 (0.58) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL24276732 | 0.94 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL24105621 | 0.94 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL20842453 | 0.94 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL25229254 | 0.94 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938226-B2 | Abiotic anti-VEGF nanoparticle | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230029277-A1 | Abiotic Anti-VEGF Nanoparticle | MIURA YOSHIKO (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20190216744-A1 | Abiotic Anti-VEGF Nanoparticle | MIURA YOSHIKO (JP) | 2019-07-18 | — | — | US | disclosed |
| WO-2018039509-A1 | ABIOTIC ANTI-VEGF NANOPARTICLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029277-A1 | Abiotic Anti-VEGF Nanoparticle | VEGFA, KDR, FLT1 | MAPK1 2131/4885LMNA 3728/4885KDM4E 2451/4885 |
| US-11938226-B2 | Abiotic anti-VEGF nanoparticle | VEGFA, KDR, FLT1 | MAPK1 2131/4885LMNA 3728/4885KDM4E 2451/4885 |
| US-20190216744-A1 | Abiotic Anti-VEGF Nanoparticle | VEGFA, KDR, FLT1 | MAPK1 2131/4885LMNA 3728/4885KDM4E 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.